Comparison · NCT00359424-sae
Endovascular vs IV Only: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Endovascular vs IV Only: serious adverse events. Trial comparisons, record NCT00359424-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00359424-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.59 | 0.543 | 0.635 | wilson | |
| Risk in group 2 | 0.568 | 0.502 | 0.631 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0223 | -0.0566 | 0.102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.904 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 1.1 | 0.79 | 1.52 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Endovascular than on IV Only | 44.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Endovascular | Group two will receive a lower dose or a standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) rightafter the medicine is given to check for blood clots. If a clot is not seenthen no more treatment will be given. If a clot is seen, theneurointerventionalist will then choose (based on the location andextent of the blood clot) a protocol approved endovascular treatmentgiven directly in the brain artery that will be most effective inreopening the blocked artery. | 256 | 434 | EG000 |
| Group 2 | IV Only | Group one will receive the standard dose of intravenous (IV) rt-PA alone given over an hour. | 126 | 222 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Interventional Management of Stroke (IMS) III Trial
- NCT number
- NCT00359424
- Phases
- PHASE3
- Conditions
- Stroke
- Interventions
- IV rt-PA alone, endovascular therapy
- Lead sponsor
- Joseph Broderick
- Results first posted
- 2013-12-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00359424?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00359424-sae